West Virginia § 33-54-4 Health benefit plan issuer reporting requirements

West Virginia Statutes

§ 33-54-4 — Health benefit plan issuer reporting requirements

West Virginia § 33-54-4

Ch. 33Â INSURANCE

Art. 54REQUIRING ACCOUNTABLE PHARMACEUTICAL TRANSPARENCY, OVERSIGHT, AND REPORTING ACT

This text of West Virginia § 33-54-4 (Health benefit plan issuer reporting requirements) is published on Counsel Stack Legal Research, covering West Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

W. Va. Code § 33-54-4 (2026).

Text

No later than March 1 of each calendar year, each health benefit plan issuer shall submit to the Auditor a report providing the following information for the immediately preceding calendar year:Provided, That nothing in this article should be construed as to requiring a health benefit plan issuer to disclose confidential health information protected by the Health Insurance Portability and Accountability Act:

(1)The names of the 25 most frequently prescribed prescription drugs across all plans;

(2)The percent increase in annual net spending for prescription drugs across all plans;

(3)The percent increase in premiums that were attributable to prescription drugs across all plans;

(4)The percentage of specialty drugs with utilization management requirements across all plans; and

(5)T

Free access — add to your briefcase to read the full text and ask questions with AI

No later than March 1 of each calendar year, each health benefit plan issuer shall submit to the Auditor a report providing the following information for the immediately preceding calendar year:Provided, That nothing in this article should be construed as to requiring a health benefit plan issuer to disclose confidential health information protected by the Health Insurance Portability and Accountability Act:

(1) The names of the 25 most frequently prescribed prescription drugs across all plans;

(2) The percent increase in annual net spending for prescription drugs across all plans;

(3) The percent increase in premiums that were attributable to prescription drugs across all plans;

(4) The percentage of specialty drugs with utilization management requirements across all plans; and

(5) The premium reductions that were attributable to specialty drug utilization management.